



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

EPA-SAB-EHC-89-008

October 14, 1988

OFFICE OF
THE ADMINISTRATOR

Honorable Lee M. Thomas
Administrator
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington, D.C. 20460

Subject: Science Advisory Board's review of issues relating to
the health assesment document for PHOSGENE

Dear Mr. Thomas,

The Science Advisory Board's Environmental Health Committee has completed its review of the issues pertaining to the health assessment document for phosgene, at its meeting July 14-15, 1988 in Washington, D.C.

The available data are inadequate for assessing the health effects of intermittent or chronic exposure to low concentrations of phosgene. The Environmental Health Committee recommends that to help identify data gaps, that a tabulated comparison between known data on the health effects of phosgene be made with other more completely investigated compounds. While other compounds (e.g. ozone) would be chemically different, the tabulation will help provide a model for further research on phosgene. Chronic intermittent and/or lifetime exposure may be the focus of regulatory action, therefore, exposure assessment data are necessary to determine the exposure levels for health effects research. In the document, the highest concentration of phosgene reported in ambient air was 61.1ppt. Inclusion of actual environmental data, and dispersion/exposure modeling will provide a better measure of the potential hazard when chronic exposure health effects are available.


The Committee agrees with the research needs as described in the document. In chronic inhalation studies, the committee suggests that, over time, endpoints be assayed such as changes in pulmonary lavage protein content, pulmonary function and histological alterations (increased collagen, cellular damage in airways and alveoli, hyperplasia and tumors). If phosgene is a carcinogen the primary targets would likely be the lung and nose.

The concentration times time (C_xT or exposure concentration times time of exposure) relationship appears to be invalid at low concentrations (Diller, Bruch, and Dehnen, 1985) and it is recommended that C_xT not be used to extrapolate to chronic effects. Moreover, the data do not support the reversibility of phosgene toxicity. Even though there is scant evidence supporting systemic distribution of phosgene, it is possible that the chemical may be a developmental toxicant as a result of hypoxia.

The Committee concludes that the changes made in the phosgene document in response to comments of peer review panel members are reasonable. In considering the public comments the Committee recommends that studies of potential carcinogenicity, mutagenicity, reproductive and developmental effects of phosgene must be included in the document whether they are positive or negative. Phosgene may be a lung carcinogen in animals chronically exposed by inhalation but no adequate studies have been performed to examine this possibility. The compound may be a developmental toxicant as a result of hypoxia.

We appreciate the opportunity to conduct this particular scientific review. We request that the Agency formally respond to the scientific advice provided herein.

Sincerely,


Norton Nelson
Chairman, Executive Committee


Richard A. Griesemer
Chairman
Environmental Health Committee

U.S. ENVIRONMENTAL PROTECTION AGENCY
SCIENCE ADVISORY BOARD
ENVIRONMENTAL HEALTH COMMITTEE
July 14-15

Dr. Richard A. Griesemer [CHAIR], Director, Division of Toxicology Research and Testing, NIEHS, P.O. Box 12233, Research Triangle Park, NC 27709

Dr. D. Warner North [VICE-CHAIR], Principal, Decision Focus Inc., Los Altos Office Center, Suite 200, 4984 El Camino Real, Los Altos, California 94022

Dr. Gary Carlson, Department of Pharmacology and Toxicology, School of Pharmacy, Purdue University, West Lafayette, IN 47909

Dr. Phil Enterline, Department of Biostatistics, Graduate School of Public Health, University of Pittsburg, 130 Desoto Street, Pittsburg, PA 15261

Dr. Marshall Johnson, Professor, Department of Anatomy, Jefferson Medical College, 1020 Locust Street, Philadelphia, Pennsylvania 19107

Dr. Nancy Kim, Director, New York Department of Health, Division of Environmental Health, 2 University Plaza, Albany, New York 12203

Dr. Martha Radike, Department of Environmental Health, Medical Center, University of Cincinnati, 3223 Eden Avenue, ML #56, Cincinnati, OH 45268

Dr. Stephen M. Rappaport, Department of Biomedical and Environmental Health Sciences, Earl Warren Hal Room 317, School of Public Health, University of California, Berkeley, California 94720

Dr. Robert Tardiff, 1423 Trapline Court, Vienna, VA 22180

Dr. Bernard Weiss, Professor, Division of Toxicology, P.O. Box RBB, University of Rochester, School of Medicine, Rochester, New York 14642

Dr. Ronald Wyzga, Electric Power Research Institute, 3412 Hillview Avenue, P.O. Box 1041, Palo Alto, California 94303

LIASON MEMBER

Dr. David Gaylor, National Center for Toxicological Research, Jefferson, Arkansas 72079

EXECUTIVE SECRETARY

Dr. C. Richard Cothorn, Executive Secretary, Science Advisory Board
[A-101F] U.S. Environmental Protection Agency, Washington, D.C. 20460

WORKSHOP GROUP

Dr. James C. Lamb, Senior Assistant, Jellinek, Schwartz, Connolly and Freshman Inc. 1350 New York Avenue NW, Suite 400, Washington, D.C. 20005

Dr. John McLachlan, Chief, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709

Dr. Bernard Schwetz, Chief Assistant of Toxicology Branch, NIEHS, P.O. Box 12233,
D-402, Research Triangle Park, NC 27709

Dr. Anthony Scialli, Director, Reproductive Toxicology Center, 2425 L St. NW,
Washington, D.C. 20037-1485

Dr. Peter Working, Genentech Inc., 460 Point Bruno Blvd., South San Francisco, CA
94080